Doravirine is a non-nucleoside reverse transcriptase inhibitor used in combination with other antiretrovirals to treat HIV-1 infections. Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg).
- Mechanism
- Curator reviewed · 6 references
Doravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor of HIV-1. Reverse transcriptase is the enzyme with which HIV generates complementary DNA (cDNA) to its RNA genome - this cDNA is then inserted into the host cell genome, where it can be transcribed into viral RNA for the purposes of replication. Doravirine inhibits HIV-1 replication by non-competitively inhibiting HIV-1 reverse transcriptase. Doravirine does not, however, inhibit the human cellular DNA polymerases α, ß, and mitochondrial DNA polymerase γ.
- Primary indication
- Doravirine is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history.Curator reviewed · 5 structured indications
- Formula / weight
- C17H11ClF3N5O3 · 425.749 g/mol (avg)
- First approval
- Canada, 2018 · United States, 2018 · European Union, 2021
- Code names
- MK-1439
- Brand names
Resolves to
ZIAOVIPSKUPPQW-UHFFFAOYSA-NSMILESCN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)FWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Doravirine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account